Lamirande Elaine W, DeDiego Marta L, Roberts Anjeanette, Jackson Jadon P, Alvarez Enrique, Sheahan Tim, Shieh Wun-Ju, Zaki Sherif R, Baric Ralph, Enjuanes Luis, Subbarao Kanta
Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20892, USA.
J Virol. 2008 Aug;82(15):7721-4. doi: 10.1128/JVI.00304-08. Epub 2008 May 7.
The immunogenicity and protective efficacy of a live attenuated vaccine consisting of a recombinant severe acute respiratory syndrome (SARS) coronavirus lacking the E gene (rSARS-CoV-DeltaE) were studied using hamsters. Hamsters immunized with rSARS-CoV-DeltaE developed high serum-neutralizing antibody titers and were protected from replication of homologous (SARS-CoV Urbani) and heterologous (GD03) SARS-CoV in the upper and lower respiratory tract. rSARS-CoV-DeltaE-immunized hamsters remained active following wild-type virus challenge, while mock-immunized hamsters displayed decreased activity. Despite being attenuated in replication in the respiratory tract, rSARS-CoV-DeltaE is an immunogenic and efficacious vaccine in hamsters.
利用仓鼠研究了一种缺失E基因的重组严重急性呼吸综合征(SARS)冠状病毒减毒活疫苗(rSARS-CoV-DeltaE)的免疫原性和保护效力。用rSARS-CoV-DeltaE免疫的仓鼠产生了高血清中和抗体滴度,并在上、下呼吸道免受同源(SARS-CoV Urbani)和异源(GD03)SARS-CoV的复制。rSARS-CoV-DeltaE免疫的仓鼠在受到野生型病毒攻击后仍保持活跃,而模拟免疫的仓鼠活动减少。尽管rSARS-CoV-DeltaE在呼吸道中的复制能力减弱,但它在仓鼠中是一种具有免疫原性且有效的疫苗。